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The health of an individual depends upon their DNA as well as upon environmental factors (environome or
exposome). It is expected that although the genome is the blueprint of an individual, its analysis with that
of the other omes such as the DNA methylome, the transcriptome, proteome, and metabolome will further
provide a dynamic assessment of the physiology and health state of an individual. This review will help to
categorize the current progress of omics analyses and how omics integration can be used for medical
research. We believe that integrative personal omics profiling (iPOP) is a stepping stone to a new road to
personalized health care and may improve disease risk assessment, accuracy of diagnosis, disease moni-
toring, targeted treatments, and understanding the biological processes of disease states for their preven-
tion.Health care has always been personal in that patients are treated
according to their individual symptoms, exposures, and family
history. Current medical exams measure a limited number of
components in healthy individuals and slightly more in those
with suspected diseases. However, the revolution in new tech-
nologies allows measurements of DNA and other molecules at
an unprecedented level for more precise diagnostics and treat-
ment at a personalized level.
A personal genome, the 6 billion nucleotides that encode
each individual, can now be deduced at a reasonable cost.
The effects of environmental exposures (pathogens, food, and
other contacts) are also likely to shape one’s physiology and their
effects on other omes such as epigenome (DNA methylation),
transcriptome (RNA), proteome, metabolome, auto-antibo-
dyome, and microbiome (summary in Table 1) can be measured
by many new technologies (e.g., DNA sequencing, mass spec-
trometry, protein microarrays). These measurements, along
with standard medical tests, are expected to capture the addi-
tional in-progress omic dimensions of an individual’s biological
condition. The integration of omics information, referred to as
integrated personal omic profiling (iPOP), is expected to better
assist in health care in many ways including disease risk assess-
ment, early and accurate diagnosis, monitoring disease progres-
sion, targeted therapeutic treatments, understanding the biolog-
ical basis of disease states, and disease prevention.
Omics information can in principle be collected from a variety
of tissues and cell types, although for medical purposes typically
only accessible fluids such as blood or urine are analyzed in
healthy individuals. Of particular importance in such studies is
the collection of longitudinal information so that changes can
be identified during the onset of disease states. However, for in-
dividuals with diseases, biopsies and surgically removed sam-
ples can be analyzed and subjected to detailed analyses.
The use of ‘‘-ome’’ or ‘‘-omics’’ as a suffix to represent an en-
compassing new field of study is rapidly growing; in 2010, over
200 omic types were annotated in Medline (McDonald et al.,
2012). In this review, iPOP collection was performed at rela-
tively-healthy time points, which was compared to un-healthy660 Chemistry & Biology 20, May 23, 2013 ª2013 Elsevier Ltd All righstates (viral infections, green figure in Figure 1D). iPOP can be
implemented over a lifetime; it is particularly informative with in-
dividuals with high disease risk assessment (from genome), and/
or family histories of illness. This will allow for analysis of patterns
in disease manifestation, progression, and ideally identification
of gene/pathway targets for treatment, many of which are hy-
pothesized to overlap in large-scale population iPOP studies
(personalized4 population).
More than Meets the Eye: The Complexity of
Personalized Omics
The 1941 article communicating the ‘‘one-gene/one-enzyme/
one-function’’ hypothesis by Beadle and Tatum discussed the
first insights that this was ‘‘ranging from simple one-to-one rela-
tions to relations of great complexity’’ (Beadle and Tatum, 1941).
Crick in 1970 reassessed his ‘‘central dogma of molecular
biology’’ and discussed the intricate inter- and intrarelationships
between DNA 4 RNA 4 proteins (Crick, 1970). A myriad of
different omes can currently be measured, each with its own
contributions and challenges to detect disease states. Current
research continues to reveal the multifaceted mechanisms first
within each omic level, as well as the crosstalk between the
omes.
Genome: DNA
The reference human genome was ‘‘completed’’ in 2003 (Geno-
mics, 2004) and is a haploid composite of multiple individuals. It
has been revised over the years but still contains several gaps
and errors. Since then, the sequences of a large number of hu-
man genomes have been determined, including those done for
the Personal Genomes Project and the International Hapmap
Project. Many of these have been determined at low coverage
as part of the 1000 Genomes Project (Abecasis et al., 2010). In
personal genome sequencing, genomes are typically sequenced
using short-read technologies (currently 100 bp) and variants
are called relative to the reference genome (Flicek et al., 2011;
Snyder et al., 2010). The variants fall into three classes: (1) single
nucleotide variations (SNVs), (2) small insertion and deletions (in-
dels) typically 1–100 bp, and (3) structural variants, which arets reserved
Table 1. Selected Topics in the Expanding World of Omics
-ome Level Description Selected Resources
Genome DNA complete/whole DNA sequence, chromosomes http://www.personalgenomes.org/
http://www.1000genomes.org/
dbSNP: http://www.ncbi.nlm.nih.gov/snp
Exome DNA DNA sequence assoc. with coding regions http://www.nhlbi.nih.gov/resources/exome.htm
http://www.nhlbi.nih.gov/resources/
geneticsgenomics/programs/mendelian.htm
Epigenome DNA/RNA DNA methylation and histone modification
can affect chromatin and gene expression
NIH Roadmap Epigenomics Mapping Consortium
http://www.roadmapepigenomics.org/
Methylome DNA DNA methylation
Regulome DNA binding
regions
regulation factors that affect gene expression ENCODE: Encyclopedia of DNA Elements
http://www.genome.gov/ENCODE/




Splice-ome RNA alternative splicing (not the spliceosome complex) http://jbirc.jbic.or.jp/h-dbas/
Editome RNA RNA edits, variants not present in DNA
miRNome RNA miRNAs http://genetrail.bioinf.uni-sb.de/
wholemirnomeproject/
Proteome protein protein expression, isoforms http://www.humanproteinpedia.org/
http://www.hprd.org/
Autoantibodyome protein antibody targeted against one’s own protein(s)




Metagenome DNA genomes of multiple organisms https://www.ebi.ac.uk/metagenomics/




Interactome all networks of all omic interactions http://interactome.dfci.harvard.edu/




The table summarizes the different omes and their application to personalized medicine. Bolded ‘‘-omes’’ are those used in an initial iPOP study by
Chen et al., 2012.
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sions, and translocations. To assign variants to each chromo-
some (i.e., DNA phasing) several methods can be used such
as sequencing of family members and imputation using known
haplotypes. DNA phasing is important in order to identify
compound heterozygous mutations (different mutations that lie
in the same gene but on different chromosomes) and to better
interpret disease risk. Other key distinctive features of the
genome are pseudogenes, transposons, and repetitive regions,
which collectively comprise about 45% of the genome. Whereas
much attention has been placed on coding sequences (which
comprise only 1.5% of the genome and can be targeted by
exome sequencing), a growing focus is on noncoding regions
of DNA (Boyle et al., 2012; Chen et al., 2012). For example,
new insights based on the ENCODE (Encyclopedia of DNA Ele-
ments) project have revealed millions of transcription factor-
binding sites as well as epigenetic modifications (histone marks,
chromatin accessibility, DNA methylation) that ultimately effect
the transcription landscape (Birney et al., 2007). The genome
sequence can be used to predict disease risk using two ap-
proaches: (1) examination of rare variants in protein coding
genes that are highly penetrant and associated with human dis-
ease and (2) examination of complex disease risk by integration
of information over multiple variants, each of low penetranceChemistry & B(Ashley et al., 2010). Curation of such DNA variants relative to
different forms of cancers has been ongoing since 2005 as
part of The Cancer Genome Atlas (TCGA). In spite of the many
advances in this area, interpretation of most variants remains a
formidable challenge requiring considerable effort (we spend
100 manual hours per genome) and, in many cases, the effects
of personal variants remain unclear.
Transcriptome: RNA
Analysis of gene expression levels of mRNAs and their various
spliced isoforms is typically the main focus of transcriptomics,
although there is interest in other RNAs such as rRNA, tRNA,
miRNA, lincRNA, and snoRNAs (Table 1). Changes in an individ-
ual’s RNA expression are tissue specific and time course depen-
dent. Measurements of RNA transcripts by RNA sequencing
afford a very large dynamic range (greater than five orders of
magnitude), enabling the detection of transcripts expressed at
a low level. Deep RNA sequencing allows for more accurate
quantification of expression of the heterozygous variants,
namely, allelic specificexpression (ASE).Similarly thoseRNAvar-
iants that are absent at the DNA level suggest the occurrence of
posttranscriptional RNA editing (editome), typically in mammals
either A/G or I and C/U (Chen et al., 2012; Li et al., 2009).
Many of these RNA variants result in missense or nonsense




Figure 1. Schematic Representing the Implementation of iPOP for Personalized Medicine
(A) Participant tissue sample (e.g., PBMC) is collected, while environment (including diet, exercise, etc.), medical history, and clinical data are recorded. T1 is the
first time point.
(B) Selected omic analysis involved in a sample iPOP study (Chen et al., 2012).
(C) Sample Circos plot (Krzywinski et al., 2009) of DNA (outer ring), RNA (middle ring), and protein (inner ring) data matching to chromosomes.
(D) iPOP performed and integrated at multiple time points: T2, T3, T4 (viral infected), and T5 up to Tn states, including disease state(s). Grey and green forms
represent a relatively healthy individual and a disease state, respectively.




The proteome and metabolome are expected to be more
closely connected to phenotype and thereby provide more
precise measures of a physiological state. Liquid chromatog-
raphy mass spectrometry (LC-MS/MS) analysis can currently
identify up to 5,000 expressed proteins, typically the most
abundant proteins in the sample. A personal proteome that
detects the variants present in an individual can be generated
using a personal reference genome or transcriptome enabling
a better detection of protein variants. Like RNA, protein ex-
pression is time course- and tissue-dependent. Increasing evi-
dence shows that the expression levels of RNAs are only
partially correlated with those of their protein counterparts (de
Sousa Abreu et al., 2009). Proteins can undergo several modi-
fications, their detection limited by current methods. Such
modifications include phosphorylation (via kinases), ubiquiti-
nation, methylation, acetylation, glycosylation, oxidation, and
nitrosylation.
Metabolome profiling is a considerable challenge due to the
diverse chemical nature of metabolites (e.g., hydrophobic/hy-662 Chemistry & Biology 20, May 23, 2013 ª2013 Elsevier Ltd All righdrophilic, basic/acidic). It is typically either targeted (e.g., GC-
MS), which allows the analysis of several hundred metabolites,
or untargeted (LC-MS), which reveals >4,000mass spectrometry
peaks, a fraction of which can be tentatively assigned based on
column retention time and molecular mass. Nonetheless, key
metabolites have been associated with important diseases
such as type 2 diabetes (glucose and branched amino acids)
and cancer.
Integrative Analyses of Omics Information
Omics information has been combined to better understand and
monitor healthy and disease states. Two recent examples
include cancer and healthy person profiling.
Cancer Omics
Cancer omics began with genome sequencing, which revealed
that each individual cancer contains unique somatic mutations.
These mutations often fall into particular pathways, for example
in ovarian cancer patients, mutations often occur in PIK3/Rb,
BRCA1 and Notch pathways (Cancer and Atlas, 2011). Morets reserved
A B
Figure 2. Highlights in iPOP
(A) Integration of DNA variants to assess disease risk (RiskGraph, top panel) and a sample pharmacogenome (bottom panel). Arrow heads point in the direction of
the change in posttest probability (%).
(B) Expression analysis (partial heatmap) of the transriptome and proteome over a time course spanning a respiratory syncytial viral (RSV) infection, with glucose
monitoring (bottom, onset of T2D). Genes showing relative change in expression are clustered and represented as a network of inter- and intraconnected
pathways: RNA (blue circle), protein (yellow square), and both RNA and protein (green hexagon). An example of a metabolite identified during the time course is
also shown (inset panel).
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information, notably RNA-expression, DNA methylation, and
phosphoprotein studies (using reverse phase arrays). These
studies have revealed common genes and pathways that can
be affected. For example, although mutations in the EGFR
gene are uncommon in colon cancer, the EGFR signaling
pathway is often elevated from phosphosignaling analyses (Per-
kins et al., 2010). As such, integrative profiling is expected to
reveal such changes and provide a better understanding of the
disease state and its etiology. There is also growing value in
longitudinal genome analysis (monitoring somatic changes),
particularly in cases with early genome information and/or family
history that are associated with diseases like cancer (Dawson
et al., 2013).
Personal Omics Profiling
Chen et al. (2012) discussed the first example of iPOP in which
the complete genome was sequenced and overlaid with the cor-
responding exome, transcriptome, proteome, metabolome, and
auto-antibodyome (Figure 1). This was performed on a 54-year-
old, initially healthymale at 20 time points over the time course of
726, days which included two viral infections and the onset of
type 2 diabetes (T2D). Peripheral blood mononuclear cells
(PBMC) and serum or plasma were isolated for nucleic acid, pro-
tein, and metabolite analyses. A plethora of biologically relevant
information was gleaned using iPOP, and several novel high-
lights are summarized below (Figures 2 and 3).
Disease-Risk and Pharmacogenetic Assessment via
DNA Variants
A major component of iPOP analysis is the ability to accurately
assess disease risk. This is challenging, given both the large
number of genetic variants and the fact that many diseases likely
involve combinations of both genetic and environmental factors.
The RiskGraph (Ashley et al., 2010) takes into account age,
gender, and ethnicity as well as multiple independent disease-Chemistry & Bassociated genomic SNVs to calculate the subject’s posttest
probability (%) of illness risk (Figure 2A, top). In this case, higher
risks were shown for coronary artery disease and triglycemia
(known family history) aswell as T2D (unexpected). It is important
to note that during the course of this study, the subject ex-
perienced high levels of glucose and hemoglobin A1c (HgA1c)
and was diagnosed as diabetic. Thus, the genome information
indicated risk for a previously unsuspected disease, which the
subject acquired (and managed) during the study (Figure 2B,
bottom).
A pharmacogenetic assessment for drug response to com-
mon pharmaceuticals was also ascertained and the response
relevant to the subject potential disease treatments noted
(Figure 2A, bottom). For example, sensitivity to particular statins
(which were being taken by the subject) and metformin (which
was not used but is pertinent to diabetes) was noted. This type
of personalized matching of patients to medications has the po-
tential to greatly reduce cost, treatment time, and adverse side
effects to medications. While genome analysis is predictive,
complementary analysis can be used at the different omic levels,
including their overall crosstalk with environmental factors, to
better gauge disease progression.
RNA, Proteins, and Metabolites Exhibit Dynamic
Changes over Disease States and Provide a More
Comprehensive View inMonitoring Disease Progression
A key highlight to iPOP is monitoring changes in omics profiles
over time. Molecules that are up- or downregulated and linked
to disease states are of particular interest as they can be used
for understanding mechanisms of disease progression and, in
turn, be targets for therapeutics. An example in this study
showed that a number of RNAs, proteins, and metabolites
changed in abundance during both viral infections (human rhino-
virus [HRV] and respiratory syncytial virus [RSV]) and the eleva-
tion of glucose levels. Both gradual changes as well as aberrant
spikes in molecular profiles were systematically extracted fromiology 20, May 23, 2013 ª2013 Elsevier Ltd All rights reserved 663
Figure 3. Highlights in iPOP
(A) Sample phased DNA overlaid with RNA variant data corroborated with allelic-specific expression (ASE) ratios for the ENDOD1 gene. Maternal transcript is
expressed at 0.40, while the respective paternal transcript is expressed at 0.60. The triangle represents an indel in the paternally inherited transcript.
(B) RNA editing in BLCAP (red arrows) result in protein level amino acid changes. BLCAP is found on the reverse strand (rev), and A/G editing appear as T/C.
(C) An example of the diversity of isoforms observed in UQCR10 RNA and protein data. The two isoforms each contain the allelic-specific variant A and G
(rs76013375). Note isoform 2 spans into the intron position of DNA (faded); the true match is at the alternate spliced region located further downstream (data not
shown). RNA variant (A/G) results in amino acid change I:V, as identified in the proteome mass spectrometric data (bottom).
For (B) and (C), DNAnexus was used as a genome browser, where red nucleic acid represents mismatches to the reference genome (top). Blue and green nucleic
acid strands represent forward and reverse Illumina reads, respectively.
Chemistry & Biology
Reviewthe profiles. Notably, the biological pathways that showed spike
maxima (Figure 2B, heatmap), were those occurring post- RSV
infection, at elevated glucose (Figure 2B, bottom) and HgA1c
levels. Indeed, upregulated RNA and/or the protein levels linked
to genes involved in similar function were found to group
together. Based on GO ontology, several biological pathways
were enriched (network representation in Figure 2B, left). One
pathway was involved in glucose regulation and insulin secre-
tion, which corroborated with clinical data (and the onset of
T2D). Metabolites from overlapping time points also clustered
in similar patterns to RNA and protein data. This included lauric
acid (Figure 2B, inset), found to be associated to the sterol reg-
ulatory element binding transcription factor 1 (SREBF1) involved
in glucosemetabolism and lipid production (Nafikov et al., 2013).
Thus, changes of RNA, protein, andmetabolic components were
elucidated and provided a clearer picture of the biological
changes that occurred during disease onset and progression.
DNA Phasing to Allele-Specific Expression and RNA
Editing
Though disease risk can be estimated from DNA variants, the
expression of genes and proteins is equally, if not more, pheno-
typically relevant. In this study, additional variants were assigned664 Chemistry & Biology 20, May 23, 2013 ª2013 Elsevier Ltd All righto parental chromosomes (i.e., paternal and maternal) and het-
erozygous gene expression was monitored. The majority of
allelic-specific expression (ASE) was found at equal levels,
although a number of RNAs exhibited differential allele expres-
sion. An example is represented in Figure 3A, where ASE variants
on correspondent 30 UTRs of the ENDOD1 (an endonuclease)
transcript were each found to be differentially expressed: those
on the maternal copy at 0.40 and paternal copy at 0.60. This
data was integrated with Chip-Seq data (regulome) to further
investigate the biology of selective transcript expression.
The editome is a new field of investigation whereby variants in
RNA (undetectable in DNA) are observed. These are due to post-
transcriptional modifications. Figure 3B illustrates two consecu-
tive edit sites (red arrows) in BLCAP (bladder cancer-associated
protein gene, on the reverse strand) resulting in amino acid
changes at the protein level. A ratio of transcripts 0.20 (A/
G) was found to be edited in PMBCs, suggesting that low levels
of RNA editing are detectable (Chen et al., 2012). Edit sites are
also commonly found in noncoding regions as well as nongenic
regions, including Alus (Ramaswami et al., 2012).
Allele-specific gene expression and RNA editing can be
observed at the protein level. One example is shown ints reserved
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chondrial ubiquinol-cytochrome c reductase, are both ex-
pressed, each containing an allelic-specific variant A or G
(rs76013375). This holistic approach of integration of the tran-
scriptome with the proteome allowed for a full-scope analysis
of all the missense and nonsense changes detectable using
mass spectrometry, whereby both amino acid types, I (AUC)
and V (GUC), were expressed at the protein level (Figure 3C,
inset).
Overall, we speculate that allele-specific gene expression and
differential RNA editing is important for phenotypic differences
among individuals in disease susceptibility and progression.
Progress and the Future of iPOP and Health Care
Development of iPOP and its application to an individual’s health
needs have focused on the advancement of high-throughput
technology, data storage and sharing, and world-wide bioethics
and discussion on health states and the environment.
Current genome-wide methods such as Illumina sequencing,
Complete Genomics, SOLiD (ABI), 454 Life Sciences, Ion Torrent
(Life Technologies) and other platforms are improving in cost,
speed, and quality. For genomic sequencing, the cost has
greatly reduced from $500 million to $1 billion/genome in 2001
to less than $5,000/genome (Green and Guyer, 2011). Still, there
are significant challenges such as sequencing and mapping
errors that are present from using short reads. De novo and
direct sequencing are technologies that are still under develop-
ment, with limitations in quality and depth. Likewise, the ana-
lyses of large numbers of proteomes and metabolomes can be
challenging, as can be the storage and dissemination of large
data sets.
The use of diverse technologies and the generation of large
data reflect the growing need for an amalgamation and cooper-
ation of overlapping expertise in diverse fields. In our study (Chen
et al., 2012), the least-squares spectral time-series analysis was
implemented to compensate for unevenly sampled data when
integrating the transcriptome, proteome and metabolome
(Figure 2B). This method was based on methodology developed
for astronomical observations by physicists Lomb and Scargle.
Consortiums are being formed for optimization of resources
and expertise, and omic methods such as iPOP are being recog-
nized as tangible study options in multidisciplinary sciences.
The growing understanding of the multifaceted layers of
omics, such as the regulation of ASE resulting in diverse trans-
lated products (Figure 3C), reveal the importance of an inte-
grated approach. Such studies will improve understanding of
compound heterozygous mutations (inherited and private) as
well as compensatory mutations, which may unravel the biology
of complex diseases. Longitudinal studies, whereby healthy
versus disease states can be compared (Figures 1D and 2B),
reveal clearer biological patterns matched to an individual
captured in a dynamic environment. Thus, more precise
methods of monitoring, treatment, and prevention can be
applied and fine-tuned with each patient. In turn, iPOP studies
overlapping large cohorts are underway for a better understand-
ing of overall biochemical mechanisms in disease manifestation
and progression.
The medical interpretation of iPOP is a balance of both nature
(omics) and nurture (environment). Major concerns in data inter-Chemistry & Bpretation and redistribution to the individual (and to the public)
raise bioethical questions on information privacy (deidentifica-
tion). The challenging path from the laboratory to the clinic is
also being addressed; few biomarkers of the 150,000 described
through research have made it to the clinic (Poste, 2011), and in
our study, it is as yet undetermined which sets of markers are
likely to be of highest clinical significance. Genetic counselors
partnered with medical staff are indispensable for a patient as-
sessing their omics and medical choices, both biologically and
psychologically. Particularly in cases of high disease risk, the in-
dividual can make a more informed decision on their medical
course of action. In this light, iPOP has opened the way to a
new perspective on the plasticity of biological processes that un-
derlie health states in flux. Integrated personal omics profiling is
facilitating the discovery of novel genes and pathways and their
interplay with the environment, allowing for improved health
monitoring and targeted therapeutics, and leading the way to
improved personalized health care.ACKNOWLEDGMENTS
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